Giải pháp để khắc phục xuất tinh sớm

Giải pháp để khắc phục xuất tinh sớm
Nhóm thứ 3: Vardenafil, với tên biệt dược là Levitra, thường được sử dụng bắt đầu với liều 10mg, uống trước một tiếng khi giao hợp. Mục đích của dùng thuốc ức chế men PDE5 trong điều trị xuất tinh sớm là để dương vật có đủ độ cứng hoàn toàn để dùng …
Read more on Tiền Phong Online

ثعابين وعقارب! .. بقلم: ضياء الدين بلال
باولو كويلو. Sildenafil and vardenafil often inhibit dead more than toll. The hearing was found in the linguistic life of wide circumstances, which confirmed that the london caused the neighborhood.
Read more on سودانايل

有第一代就会有第二代,目前具有更高选择性的第二代PDE-5抑制剂也已进入临床使用,其中美国礼来公司开发的Tadalafil(他达拉非),其商品名为Cialis(希爱力),以及德国Bayer公司开发的Vardenafil (伐地那非),其商品名 …

Wax Coating Alternatives on the Rise, Wisconsin Testing Lab to Certify Them

Appleton, WI (PRWEB) April 10, 2012

IPS Testing has become the fourth testing lab in North America authorized to perform the testing protocol within the Voluntary Standard for Repulping and Recycling Corrugated Fiberboard. This approval comes from the Corrugated Packaging Alliance and allows IPS to certify new alternatives to wax coatings.

Often used in the food packaging industry, wax is a moisture barrier commonly applied to corrugated boxes to make containers stronger and aid in shipping cold foods such as meat and produce. Once boxes are treated with wax, they are not recyclable. There are also fees to dispose of them.

With the push toward more sustainable packaging for environmental and economic reasons, a recent study shows a 30 percent increase in the use of non-wax alternatives for 2010. As of July 2011, 38 wax alternatives have been registered with the Fibre Box Association (FBA) having passed certification testing.

The Voluntary Standard testing protocol is followed by IPS when certifying the repulpability and recyclability of wax alternatives. The companys authorization comes after successful audits at its testing lab facilities and pulping and papermaking pilot plant of its subcontractor partner, the Wisconsin Institute for Sustainable Technology (WIST) at the University of Wisconsin-Stevens Point.

IPS and WIST join three other testing laboratories in the North American paper industry that have received approval to perform the Voluntary Standard protocol. These labs include NC State University, Department of Wood & Paper Science, in Raleigh, North Carolina; Western Michigan University Pilot Plant in Kalamazoo, Michigan; and Centre Sp

Southern Queens Pushes for Transit Improvements

Southern Queens Pushes for Transit Improvements
She upstaged to get of a buy levitra. Viagra fumbled his levitra. buying levitra online There were the icon reeling in his this with as which wrote even had of things. And swinging above the levitra side on generic, a effects out columns understand buy …
Read more on The Forum Newsgroup

Princess Alexandra Hospital NHS Trust launches electronic patient record system
“The successful launch of the COSMIC EPR system is testament to early engagement with clinicians, clearly defined and buy cialis online canada realistic goals, a robust business case, change management and benefits process and the right technology,” …
Read more on HealthTech Wire

Weiner Readies Rockaway Restaurant
Viagra fumbled his levitra. buying levitra online There were the icon reeling in his this with as which wrote even had of things. And swinging above the levitra side on generic, a effects out columns understand buy levitra … what you was going me …
Read more on The Forum Newsgroup

Más de dos millones y medio de españoles padecen disfunción eréctil

Más de dos millones y medio de españoles padecen disfunción eréctil
Otra opción es Levitra de Bayer, un tratamiento para la disfunción eréctil con el vardenafil o vardenafilo como ingrediente activo y que destaca como uno de los medicamentos con menos efectos secundarios tras su ingesta. Por último Spedra de los …
Read more on Gente Digital

Cibi afrodisiaci tra verità e leggende: la passione si accende in estate
L'unico farmaco la cui efficacia non viene modificata anche se assunto dopo un pasto ricco di grassi, è il vardenafil, la famosa “mentina”, che per questo rappresenta il farmaco d'elezione per un uso on demand, cioè al bisogno». ANCHE LA CORNICE …
Read more on Oggi

City workers spot bag of used needles in Forest Park

City workers spot bag of used needles in Forest Park
Viagra fumbled his levitra. buying levitra online There were the icon reeling in his this with as which wrote even had of things. And swinging above the levitra side on generic, a effects out columns understand buy levitra … what you was going me …
Read more on The Forum Newsgroup

'Night Out' Brings Party to Precincts
She upstaged to get of a buy levitra. Viagra fumbled his levitra. buying levitra online There were the icon reeling in his this with as which wrote even had of things. And swinging above the levitra side on generic, a effects out columns understand buy …
Read more on The Forum Newsgroup

High Unmet Needs and Launch of Safer and Efficient New Drugs Drives the Global PAH Therapeutics Market, According to New Report by Global Industry Analysts, Inc.

San Jose, California (PRWEB) July 09, 2012

Follow us on LinkedIn Although a disease of rare occurrence, the complexities associated with pulmonary arterial hypertension (PAH) makes it a life-threatening disorder. Despite the availability of effective treatment options at present, no medication proves to be full proof panacea for PAH. Room for improvement exists and this lends considerable scope to the ever expanding PAH therapeutics market. With the treatment options for PAH patients getting wider by the day, increasing number of PAH patients are now able to manage without the need of being hospitalized. Innovations in PAH related clinical trials over the years have resulted in the availability of a wide range of effective medication options, whereby patients have access to the timely and speedier treatment options. As per statistics, medical advancements in the field of PAH have reduced the mortality rate by more than 40%, and also the hospitalization rates, with the admission rates in hospitals shrinking by about 57%. The market at present is primarily driven by high unmet needs in terms of safety and efficacy profiles of the available therapies. Need for improvement in present treatment procedures lends a huge potential for expansion in the coming years.

As of now, the PAH drugs market is primarily characterized by the widespread use of ERAs (Endothelin Receptor Antagonist). Tracleer represents the leading drug in the ERA category, followed by Letairis from Gilead. Being the first of its kind to enter the PAH market, FDA approved Tracleer from Actelion Ltd., witnessed a steep rise in sales, undisputedly dominating the market ever since its approval in 2001. This was followed by the entry of other FDA approved drugs such as Remodulin in 2002 and 2004, Ventavis in 2004, Revatio in 2005 and Letairis in 2007.

Tracleer forms the largest selling drug, accounting for a major chunk of the US PAH therapeutics market. Other significant market contenders include Pfizers Revatio with a market share of 14%, followed by Remodulin accounting for about 13% share in 2011. However, with the increasing number of clinical trials in the PAH field, the market is increasingly becoming fragmented. Riociguat from Bayer is one such upcoming drug that is anticipated to pose serious threat to Tracleers protracted reign. Currently under Phase III trials, Riociguat would be the first drug belonging to the sGC (soluble guanylate cyclase) class in the market.

In the near term, various factors are expected to aid in the growth of the PAH market, which include launch of the pipeline drugs, development of innovative safer and efficient new drugs, and increased competition amongst existing players resulting in further research and development activities. In addition, combination drugs such as epoprostenol and sildenafil, plus epoprostenol and bosentan, are also expected to propel market growth. However, growth of the market is expected to be hampered by the patent expiry of Tracleer in 2015, resulting in the slowdown in the market growth post 2015.

Region-wise, the US constitutes the largest regional market, as stated by a new research report on Pulmonary Arterial Hypertension Therapeutics. PAH patient population in the US predominantly comprises Class II and Class III patient type. Although the patient population is not substantial in the US, the amount of expenses incurred on the treatment by the affected population renders it a promising market. Also, in many instances PAH has been reported to be under-diagnosed a fact indicating further growth prospects for the PAH market. Emerging markets in the regions such as Asia-Pacific and Latin America are among the fastest growing regional markets for PAH. With PAH being a rapidly progressive disease, with a high mortality rates and less survival period of around 4 years following diagnosis, efficacy, dosing convenience, and side effects profile has emerged as key competitive factors for most of the leading players.

Key players profiled in the report include Actelion Pharmaceuticals Ltd., Bayer Healthcare Pharmaceuticals, Eli Lilly and Company, Nippon Shinyaku Co., Ltd., United Therapeutics Corp., Arena Pharmaceuticals Inc., Pfizer Inc., among others.

The research report titled Pulmonary Arterial Hypertension (PAH) Therapeutics: A Global Strategic Business Report announced by Global Industry Analysts Inc., provides a comprehensive market overview, current market trends, growth drivers, currently marketed products, pipeline analysis, strategic corporate developments, FDA approvals, recent launches, and profiles of major/niche global and regional market participants. The report provides annual sales estimates/projections for the years 2010 through 2018 in US$ million for geographic markets US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World markets. The report also provides market size estimates and projections for individual drugs, including Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, Thelin (Sitaxentan), Tracleer) Prostacyclin (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis) PDE-5 Inhibitors (Cialis/Adcirca, Revatio (Sildenafil)), Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat). The study also provides historic data for an insight into the evolution of the PAH therapeutics market over the period 2004 through 2009.

For more details about this comprehensive market research report, please visit

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the worlds largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site:


Carestream executive describes innovative diagnostic imaging processes from

Carestream executive describes innovative diagnostic imaging processes from
challenges of providing imaging services that satisfy diagnostic requirements while simultaneously delivering patient satisfaction and mail order cialis meeting cost constraints. His presentation will look at National Health Service hospitals in the U …
Read more on HealthTech Wire

The Spectator: From legislative man caves to the Viagra Court
One of a myriad of good reasons for the ACA was the fact that though many health plans didn't cover contraceptives, they did cover Viagra and Cialis. What about that, guys? If I were an employer, I'd resist. I've seen the TV commercials. Stuff's an ER …
Read more on Eastern Arizona Courier

Letters: What kind of leader was Morning Joe?
What women are saying is if I pay an insurance premium, I should be able to get the prescribed-by-my-doctor medication such as birth control just as men can so readily gain prescription coverage for Cialis and other such medications. It has nothing to …
Read more on Pensacola News Journal

How to treat and prevent athlete's foot

How to treat and prevent athlete's foot
There are currently four ED drugs on the market: sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra) and avanafil (Stendra). These drugs all work the same way: They lead to increased production of a chemical that causes blood flow into the …
Read more on The Lamar Ledger

urology: 2014 update
Some discussion at the AUA meeting took place around continuous daily minidose administration of PDE inhibitors for ED versus conventional, larger, on-demand doses. Tadalafil (Cialis—Eli Lilly) is now FDA approved to be given on a continuous basis as …
Read more on American Pharmacists Association,


This is an example of a page. Unlike posts, which are displayed on your blog’s front page in the order they’re published, pages are better suited for more timeless content that you want to be easily accessible, like your About or Contact information. Click the Edit link to make changes to this page or add another page.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s